Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2

被引:43
作者
Termrungruanglert, W [1 ]
Tresukosol, D [1 ]
Vasuratna, A [1 ]
Sittisomwong, T [1 ]
Lertkhachonsuk, R [1 ]
Sirisabya, N [1 ]
机构
[1] Chulalongkorn Univ, Fac Med, Gynecol Oncol Unit, Dept Obstet & Gynecol, Bangkok, Thailand
关键词
cervical cancer; neoadjuvant chemotherapy; gemcitabine;
D O I
10.1016/j.ygyno.2005.01.048
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives. This study aimed to evaluate the efficacy and toxicity of gemeitabine in combination with cisplatin as neoadjuvant therapy in patients with cervical carcinoma stage IB2. Patients and methods. Chemotherapy-naive patients with histologic diagnosis o squamous cell cervical carcinoina staged as IB2 were treated with 2 cycles of cisplatin (70 mg/m(2) on day 1) and gemeitabine (1000 mg/m(2) on (lays 1 and 8), given every 21 days. After chemotherapy, patients underwent radical hysterectomy and pelvic lymphadenectomy. Patients judged to have a non-resectable disease were treated with standard pelvic radiation. Results. Between September 2000 to March 2004, 28 patients were enrolled in the study of which 27 were evaluable for efficacy and toxicity. The mean age was 39 years (30-55). The overall clinical response rate was 88.9%. (24 27), with complete response (CR) in 9/27 patients (33.3%) and partial response in 15/27 patients (55.5%). Three patients (11.1%) did not respond and nobody progressed. A pathological CR was noted in 2 of 24 patients who underwent radical surgery. The 3 non-responding patients were subsequently treated with radiation and achieved CR. Grades 3 or 4 neutropenia, anemia, or thrombocytopenia was observed in 7,4%, and 3.7% patients respectively. Non-hematological toxicity was mild except grade 3 nausea/vomiting in 18.5% patients. At median follow-tip time of 36,7 months (range 7-51 months), the 3-year survival was 88.9%. Conclusion. Neoadjuvant treatment with gemeitabine/cisplatin combination for patients with cervical cancer (stage 1132) appears encouraging, with manageable and acceptable toxicity profile, (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 50 条
  • [21] Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery
    Nasu, Kaei
    Hirakawa, Tomoko
    Okamoto, Mamiko
    Nishida, Masakazu
    Kiyoshima, Chihiro
    Matsumoto, Harunobu
    Takai, Noriyuki
    Narahara, Hisashi
    RARE TUMORS, 2011, 3 (01) : 18 - 20
  • [22] Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer
    Huang, Yuhui
    Chen, Lei
    Cai, Jing
    Yang, Lu
    Sun, Si
    Zhao, Jing
    Xiong, Zhoufang
    Wang, Zehua
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)
  • [23] Neoadjuvant chemotherapy followed by radical surgery reduces radiation therapy in patients with stage IB2 to IIA2 cervical cancer
    Yuhui Huang
    Lei Chen
    Jing Cai
    Lu Yang
    Si Sun
    Jing Zhao
    Zhoufang Xiong
    Zehua Wang
    World Journal of Surgical Oncology, 20
  • [24] Neoadjuvant chemotherapy followed by radical trachelectomy versus upfront abdominal radical trachelectomy for patients with FIGO 2018 stage IB2 cervical cancer
    Li, Xiaoqi
    Jiang, Zhaoxia
    Lu, Jing
    Chen, Xiaojun
    Ge, Huijuan
    Wu, Xiaohua
    Li, Jin
    GYNECOLOGIC ONCOLOGY, 2023, 169 : 106 - 112
  • [25] Tailoring neoadjuvant chemotherapy for a pregnant patient diagnosed with IB2 squamous cervical carcinoma
    Babkova, Anna
    Robova, Helena
    Malikova, Hana
    Drozenova, Jana
    Pichlik, Tomas
    Halaska, Michael J.
    Rob, Lukas
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 56
  • [26] Outcome of patients with bulky IB (≥ 6 cm) cervical squamous cell carcinoma with and without cisplatin-based neoadjuvant chemotherapy
    Wang, Peng-Hui
    Chang, Yen-Hou
    Yang, Ying-Hui
    Chang, Wen-Hsun
    Huang, Shu-Yun
    Lai, Chiung-Ru
    Juang, Chi-Mou
    Chen, Yi-Jen
    Horng, Huann-Cheng
    Wen, Kuo-Chang
    Ng, Heung-Tat
    Yuan, Chiou-Chung
    Chao, Kuan-Chong
    Yen, Ming-Shyen
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2014, 53 (03): : 330 - 336
  • [27] Efficacy of neoadjuvant chemotherapy plus radical surgery in patients with bulky stage II cervical squamous cell carcinoma: A retrospective cohort study
    Qin, Tiansheng
    Zhen, Jieyu
    Zhou, Meiying
    Wu, Huifang
    Ren, Rui
    Qu, Bo
    Wang, Hailin
    INTERNATIONAL JOURNAL OF SURGERY, 2016, 30 : 121 - 125
  • [28] Neoadjuvant chemotherapy with ifosfamide, cisplatin, and vinorelbine in advanced squamous cell carcinoma of the cervix
    Vallejo, CT
    Pérez, JE
    Domínguez, ME
    Leone, BA
    Machiavelli, MR
    Lacava, JA
    Romero, AO
    Ortiz, EH
    Grasso, S
    Amato, S
    Rodríguez, R
    Barbieri, M
    Acuña, JR
    Focaccia, G
    Suttora, G
    Scenna, M
    Boughen, JM
    Acuña, LAR
    Langhi, MJ
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (05): : 481 - 486
  • [29] Neoadjuvant Chemotherapy Followed by Simultaneous Robotic Radical Trachelectomy and Reversal of Tubal Sterilization in Stage IB2 Cervical Cancer
    Hamed, Ali Hassan
    Shepard, Marguerite K.
    Maglinte, Dean D. T.
    Ding, Sandra
    Del Priore, Giuseppe
    JSLS-JOURNAL OF THE SOCIETY OF LAPAROENDOSCOPIC SURGEONS, 2012, 16 (04) : 650 - 653
  • [30] NEOADJUVANT CHEMOTHERAPY WITH CISPLATIN, VINCRISTINE, AND BLEOMYCIN AND RADICAL SURGERY IN EARLY-STAGE BULKY CERVICAL-CARCINOMA
    CHANG, HC
    LAI, CH
    CHOU, PC
    TSENG, CJ
    CHANG, TC
    HSUEH, S
    HO, YS
    SOONG, YK
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 30 (04) : 281 - 285